Share this video  

AACR 2021 | Treating ER+ breast cancer patients with endocrine therapy resistance

Nikhil Wagle, MD, Dana-Farber Cancer Institute, Boston, MA, outlines mechanisms of resistance to endocrine therapies in estrogen receptor-positive (ER+) metastatic breast cancer, such as alterations in the estrogen receptor, alternative pathway activation and subtype alteration. Dr Wagle describes how different approaches are required to treat patients with different mechanisms of resistance. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.


Nikhil Wagle, MD, has participated in a consultancy/advisory role for Eli Lilly, has received grant support from Puma Biotechnologies, and has participated in a scientific advisory board for and is a stockholder of Relay Therapeutics.